This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
But the vascular disrupting agent’s unexpected success in a cancer indication might not be as resounding as it seems.
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.